BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28244691)

  • 1. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
    Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
    J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.
    Gao Y; Zhang Z; Li K; Gong L; Yang Q; Huang X; Hong C; Ding M; Yang H
    Cell Death Dis; 2017 Jul; 8(7):e2924. PubMed ID: 28703793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
    Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
    Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
    Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
    Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
    Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
    Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
    Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
    Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
    Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
    Du Z; Qin R; Wei C; Wang M; Shi C; Tian R; Peng C
    Dig Dis Sci; 2011 Mar; 56(3):741-50. PubMed ID: 20683663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
    El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
    Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
    Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The low chamber pancreatic cancer cells had stem-like characteristics in modified transwell system: is it a novel method to identify and enrich cancer stem-like cells?
    Wang D; Zhu H; Liu Y; Liu Q; Xie X; Zhou Y; Zhang L; Zhu Y; Zhang Z; Su Z
    Biomed Res Int; 2014; 2014():760303. PubMed ID: 24689055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
    Kuo YC; Kou HW; Hsu CP; Lo CH; Hwang TL
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.
    Suzuki S; Okada M; Shibuya K; Seino M; Sato A; Takeda H; Seino S; Yoshioka T; Kitanaka C
    Oncotarget; 2015 Jan; 6(1):458-70. PubMed ID: 25473894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
    Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
    Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
    Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
    Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
    Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.